Wang Jiao, Zhang Shuo, Xing Meng, Hong Seokgyeong, Liu Liu, Ding Xiao-Jie, Sun Xiao-Ying, Luo Ying, Wang Chun-Xiao, Zhang Miao, Li Bin, Li Xin
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.
Front Med (Lausanne). 2022 Aug 11;9:900916. doi: 10.3389/fmed.2022.900916. eCollection 2022.
Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation.
The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis.
The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis.
The study included eight randomized controlled studies, four single-arm studies, and four studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): -0.94; 95% CI: [-1.58, -0.31]; = 0.004]. Oral statins performed best at week eight (SMD: -0.92; 95% CI: [-1.39, -0.44]; = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20-CCR6 interaction, and reduction in the levels of inflammatory factors.
There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing.
The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects.
银屑病患者存在脂质分布异常,这增加了他们患动脉粥样硬化的风险。降脂药物在银屑病治疗中具有一定疗效,但缺乏相关循证医学评估。
本系统评价旨在评估降脂药物治疗银屑病的疗效、安全性及潜在作用机制。
检索PubMed、Embase、Cochrane对照试验中心注册库、Clinical Trial、中国知网(CNKI)、中国科技期刊数据库和万方数据库,检索时间从建库至2021年12月31日。分别采用RevMan 5.3和Cochrane偏倚风险工具进行数据分析和风险评估。银屑病面积和严重程度指数(PASI)评分是临床研究的主要结局指标。基于临床前研究,我们阐明并绘制了降脂药物治疗银屑病的作用机制。
该研究纳入了8项随机对照研究、4项单臂研究和4项[此处原文似乎不完整]研究。结果显示,降脂药物,尤其是他汀类药物,口服和外用均可显著改善银屑病皮肤病变并降低PASI评分[标准化均数差(SMD):-0.94;95%置信区间(CI):[-1.58,-0.31];P = 0.004]。口服他汀类药物在第8周时效果最佳(SMD:-0.92;95%CI:[-1.39,-0.44];P = 0.0001)。降脂药物治疗银屑病的机制可能与抑制角质形成细胞增殖、抑制CCL20-CCR6相互作用以及降低炎症因子水平有关。
关于降脂药物与银屑病的研究较少,且样本量较小,可能导致证据缺乏说服力。
目前的研究结果表明,降脂药物可缓解银屑病症状。降脂药物,尤其是他汀类药物,可用于治疗银屑病,疗效良好且副作用少。